

Emily Henkle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4880771/publications.pdf>

Version: 2024-02-01

14
papers

640
citations

840776

11
h-index

1058476

14
g-index

15
all docs

15
docs citations

15
times ranked

879
citing authors

#	ARTICLE	IF	CITATIONS
1	Nontuberculous Mycobacteria Infection Risk and Trace Metals in Surface Water: A Population-based Ecologic Epidemiologic Study in Oregon. <i>Annals of the American Thoracic Society</i> , 2022, 19, 543-550.	3.2	14
2	Comparative safety of inhaled corticosteroids and macrolides in Medicare enrollees with bronchiectasis. <i>ERJ Open Research</i> , 2022, 8, 00786-2020.	2.6	6
3	Nontuberculous mycobacterial pulmonary disease incidence among elderly patients with bronchiectasis. <i>European Respiratory Journal</i> , 2022, 59, 2200018.	6.7	1
4	Preliminary validation of the NTM Module: a patient-reported outcome measure for patients with pulmonary nontuberculous mycobacterial disease. <i>European Respiratory Journal</i> , 2020, 55, 1901300.	6.7	13
5	Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis. <i>European Respiratory Journal</i> , 2019, 54, 1801896.	6.7	31
6	Autoimmunity to bactericidal/permeability-increasing protein in bronchiectasis exhibits a requirement for <i>Pseudomonas aeruginosa</i> IgG response. <i>European Respiratory Journal</i> , 2019, 53, 1801891.	6.7	11
7	Characteristics and Health-care Utilization History of Patients With Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014. <i>Chest</i> , 2018, 154, 1311-1320.	0.8	57
8	US Patient-Centered Research Priorities and Roadmap for Bronchiectasis. <i>Chest</i> , 2018, 154, 1016-1023.	0.8	14
9	Mortality after Respiratory Isolation of Nontuberculous Mycobacteria: A Comparison of Patients Who Did and Did Not Meet Disease Criteria. <i>Annals of the American Thoracic Society</i> , 2017, 14, 1112-1119.	3.2	32
10	Long-Term Outcomes in a Population-based Cohort with Respiratory Nontuberculous Mycobacteria Isolation. <i>Annals of the American Thoracic Society</i> , 2017, 14, 1120-1128.	3.2	17
11	Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis. <i>Chest</i> , 2017, 152, 1120-1127.	0.8	36
12	Patient-Centered Research Priorities for Pulmonary Nontuberculous Mycobacteria (NTM) Infection. An NTM Research Consortium Workshop Report. <i>Annals of the American Thoracic Society</i> , 2016, 13, S379-S384.	3.2	58
13	Population-based Incidence of Pulmonary Nontuberculous Mycobacterial Disease in Oregon 2007 to 2012. <i>Annals of the American Thoracic Society</i> , 2015, 12, 642-647.	3.2	131
14	Nontuberculous Mycobacteria Infections in Immunosuppressed Hosts. <i>Clinics in Chest Medicine</i> , 2015, 36, 91-99.	2.1	219